Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology

Project description

Advanced bioimaging technology

There is an unmet worldwide need for accurate diagnosis and microscopic analysis at the point-of-care and in low-resource settings as existing infrastructure is cumbersome and expensive. Funded by the European Innovation Council, the DISRUPT project is developing a new lab-on-chip technology called 'integrated tomographic microscopy', which will revolutionise the field of biomedical imaging. By combining cutting-edge technologies and artificial intelligence, the consortium will develop tomographic microscopes that are much cheaper, lighter, and smaller. These improved microscopes are expected to find application in cancer diagnosis and research, as well as in telemedicine, offering improved resolution, sensitivity and energy efficiency.

Objective

DISRUPT aims at revolutionising the field of biomedical imaging by developing a radically new lab-a-on-chip technology: integrated tomographic microscopy. This unprecedented technique will be enabled by pushing forward the science of on-chip wireless photonics and tomography, in combination with microfluidics and artificial intelligence (AI). The CMOS compatibility of this technology represents a paradigm shift as it assures the realization of tomographic microscopes that are dramatically cheaper, lighter, and smaller than current approaches. Moreover, the singular features of the proposed solution introduce key advantages in terms of resolution, sensitivity, throughput, parallelisation, and energy efficiency. To illustrate its potential, we will show that on-chip TPM can be used for cancer detection and the identification of infected cells. Developments related to fundamental nanoantenna and diffraction tomography science, nanophotonics, nanofabrication, microfluidics, AI and clinical validation will be undertaken by a consortium comprised by 2 SME, 1 HE, 1 Non-profit RO and 2 Cancer R&D Medical institutions, with complementary expertise, leaders in their respective markets and R&D fields. This novel device is suited for many applications, such as early cancer diagnosis, cell characterisation, research on cancer and infectious diseases, immunocyte phenotyping, stem cell multipotency identification, tissue pathology, haematopathology, and analysis of infected cells. Its intrinsic mass-producible, compact, low-cost, mechanically robust, and energy-efficient feature makes this technology a future innovation driver for new developments in many biomedical application fields, and offers an alternative toolset addressing some of the emerging needs of microscopic analysis and diagnostics in low-resource settings, telemedicine applications and point-of-care, having a potentially huge societal impact fostering early diagnosis of cancer and other diseases and infections.

Coordinator

DAS PHOTONICS SL
Net EU contribution
€ 675 000,00
Address
CMNO DE VERA S/N PLANTA 2 EDIFICIO 8F
46022 Valencia
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Comunitat Valenciana Valencia/València
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 675 000,00

Participants (5)